Scleroderma Diagnostics and Therapeutics

Global Market Trajectory & Analytics

MCP16767

EXECUTIVE ENGAGEMENTS

POOL

2678
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

482
Interactions with Platform & by Email

PARTICIPANTS

82
Unique # Participated

VALIDATIONS

23
Responses Validated*

COMPANIES

42
Responses Validated*
* Login for a full stack data experience

DATE

JAN 2022

TABLES

123

PAGES

194

EDITION

7

PRICE

USD 4950

CODE

MCP16767


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

S M N T

%

VALIDATED RESEARCH *

S M N T
S M N T
S M N T
S M N T
S M N T
S M N T
S M N T
S M N T
S M N T
S M N T

* S = Strong; M = Moderate; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Scleroderma Diagnostics and Therapeutics estimated at US$2 Billion in the year 2020, is projected to reach a revised size of US$4 Billion by 2027, growing at aCAGR of 10.3% over the period 2020-2027. Localized, one of the segments analyzed in the report, is projected to record 9.5% CAGR and reach US$1.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Systemic segment is readjusted to a revised 11% CAGR for the next 7-year period.
The Scleroderma Diagnostics and Therapeutics market in the U.S. is estimated at US$598.9 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$692.8 Million by the year 2027 trailing a CAGR of 9.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.4% and 8.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

SELECT PLAYERS

Actelion Pharmaceuticals Ltd.; Bayer AG; Boehringer Ingelheim International GmbH; Corbus Pharmaceuticals Holdings, Inc.; Cumberland Pharmaceuticals, Inc.; Cytori Therapeutics, Inc.; Gilead Sciences, Inc.; Pfizer, Inc.; Sanofi SA

SEGMENTS

» Drug Class (Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers, Other Drug Classes) » Indication (Localized, Systemic)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Scleroderma Diagnostics and Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Localized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Localized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Localized by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Systemic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Systemic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Systemic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Immunosuppressive Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Immunosuppressive Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Immunosuppressive Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Endothelin receptor antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Endothelin receptor antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Endothelin receptor antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Calcium Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
China Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
France Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
Total Companies Profiled: 42

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com